about
A Review of Hormonal Contraception and Venous Thromboembolism in Adolescents.Temozolomide and radiation for aggressive pediatric central nervous system malignancies.Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics.Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility studyHealthcare burden of venous thromboembolism in childhood chronic renal diseases.Pediatric venous thromboembolism in the United States: a tertiary care complication of chronic diseases.Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic SyndromeAKI in Children Hospitalized with Nephrotic Syndrome.Recommendations for screening for thrombophilic tendencies in teenage females prior to contraceptive initiation.Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) studyThe emerging role of coagulation proteases in kidney disease.Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population.Desmopressin responsiveness in children with Ehlers-Danlos syndrome associated bleeding symptoms.Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism.Venous thromboembolism in pediatric nephrotic syndrome.Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.Thrombin-Induced Podocyte Injury Is Protease-Activated Receptor Dependent.Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.Light Transmission Aggregometry Does Not Correlate With the Severity of δ-Granule Platelet Storage Pool Deficiency.Validation Study of the Composite Score to Identify Von Willebrand Disease in Children.Thrombosis of the Abdominal Veins in Childhood.Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome.An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.Concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia.Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience.Epidemiology of bleeding symptoms and hypermobile Ehlers-Danlos syndrome in paediatrics.Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIIIFc) in the A-LONG and Kids A-LONG Studies.Pharmacokinetic characterization of recombinant factor XIII (FXIII)-A2 across age groups in patients with FXIII A-subunit congenital deficiency.Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency.Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.Reference Range of Platelet Delta Granules in the Pediatric Age Group: An Ultrastructural Study of Platelet Whole Mount Preparations from Healthy Volunteers.Characterization of a mouse model for thrombomodulin deficiencyCause-effect relation between hyperfibrinogenemia and vascular diseaseFibrinogen Columbus: a novel gamma Gly200Val mutation causing hypofibrinogenemia in a family with associated thrombophiliaThrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experienceRole of direct oral anticoagulants in patients with kidney disease
P50
Q30252146-A580424C-A1F0-4319-97C4-D9A7D50C90EBQ33366289-9878E101-5E14-4762-BB64-5F4F842B162DQ33378513-58D2279E-4AB7-449C-A14D-0C0B94ECBEFAQ35137326-4B0A7202-A2FF-4AA3-8C4E-3AF0B8B28DFFQ35220516-E7CC6B3A-4DCB-40A3-88CF-B200ECFD4BC0Q35722437-17DA89F8-6668-44E2-BCA3-9208E4198764Q36314964-C711AC68-AA40-4B6A-B888-6F2C5DF04305Q36349462-149F289F-B618-4D51-BD26-90D075424C85Q36549056-8995722F-2CF9-473C-AE78-4B274A7F0E68Q36937161-814DBB38-0E5F-429D-B3AD-6A9F7AB521FFQ37066587-EA40BEB7-4C2C-4A83-B356-7AB202800D8AQ37279179-2C6EBE73-9A9A-44BB-A788-6D9C70D8C67EQ37335537-DF05A8E6-83EF-42F4-B2F3-3F62C3B1E6E0Q37351746-02AE1AAD-7094-4F30-A1A7-AFF475EAD0B8Q38118114-8C4FA6D8-D081-454D-94C2-96BB82B7E674Q38743779-32EA1805-3D1E-419E-9EFA-A731A9C51E13Q38829694-5F7B7B20-6028-48F5-9B2C-BBA9C222933FQ38935920-D9585F26-4AFC-44C0-B61E-150FE8510CADQ39610648-86F8EAEA-B2CD-4817-AD7B-E82C8C52E0C2Q40357444-840D2440-707D-4EE1-B824-0472AF2CA461Q41457449-B3C5DB7D-A19E-47D1-8E7B-3F06ED825069Q42247724-D26C5D1D-9125-402D-BADA-6AA4B8CD4EF3Q42565179-4A144F92-1B93-419C-9926-7F44DE2721AAQ43478009-23EF0B2F-B47E-44D8-8840-D8FF290DB9A7Q43620926-BE3128DD-FBC2-4303-A4C8-A41B2912A2C7Q45067299-84CDDA94-0B7B-43B4-B4F6-BC1447B9D50AQ45857669-50E04FE0-6B47-43AB-99D5-2E18EFE5F8EDQ45862767-B224D2AA-5730-4C5F-A64B-F595A689EC4BQ45872670-3339805B-DEA1-4271-9642-CC7FEBFF3994Q48543476-5C0DDAD9-82B1-4C81-89D1-AC5BD6B9A75BQ49966943-B2A64A72-ED9B-4B5F-A155-F2AAF8901171Q52895141-6910DB42-CC8D-40CC-9BF9-09C0A9A9D4CCQ74515000-4F8257AA-BA98-4E56-9059-F60C37B286F8Q79291740-F70B346B-2450-4535-9188-37C28827656DQ80667426-8466E661-5779-4D13-9116-A92C7DFE92D5Q82655475-D5DEB850-2102-4549-A445-D2990B97717EQ89924903-F831D147-B93D-475A-9157-3FBC6EFE5813
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bryce A Kerlin
@nl
Bryce A Kerlin
@sl
Bryce A. Kerlin
@en
Bryce A. Kerlin
@es
type
label
Bryce A Kerlin
@nl
Bryce A Kerlin
@sl
Bryce A. Kerlin
@en
Bryce A. Kerlin
@es
prefLabel
Bryce A Kerlin
@nl
Bryce A Kerlin
@sl
Bryce A. Kerlin
@en
Bryce A. Kerlin
@es
P106
P1153
6603177369
P31
P496
0000-0002-1756-8271